Skip to search formSkip to main contentSkip to account menu

trioxifene mesylate

Known as: trioxifene methanesulfonate, 3,4-Dihydro-2-(p-methoxyphenyl)-1-naphthyl p-(2-(1-pyrrolidinyl)ethoxy)phenyl Ketone Methanesulfonate, Trioxifene Mesilate 
A mesylate salt form of trioxifene, a nonsteroidal selective estrogen receptor modulator (SERM). Trioxifene competitively inhibits the binding of… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Lilly 133314
trioxifene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects
Tamoxifen and trioxifene are antiestrogens that appear to have different endocrine effects when tested in rats. Whereas tamoxifen… 
1986
1986
Trioxifene mesylate in the treatment of advanced breast cancer
The efficacy of trioxifene mesylate, a new antiestrogen, in the management of advanced breast cancer was evaluated in 69 patients… 
1981
1981
A PHASE I-II evaluation of trioxifene mesylate in the treatment of advanced breast cancer
1980
1980
Trioxifene mesylate (LY 133314): a new antiestrogen which inhibits growth hormone secretion in the rat.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)